Exploring the cellular accumulation of metal complexes by Puckett, Cindy A. et al.
PERSPECTIVE www.rsc.org/dalton | Dalton Transactions
Exploring the cellular accumulation of metal complexes
Cindy A. Puckett, Russell J. Ernst and Jacqueline K. Barton*
Received 23rd October 2009, Accepted 11th November 2009
First published as an Advance Article on the web 23rd December 2009
DOI: 10.1039/b922209j
Transition metal complexes offer great potential as diagnostic and therapeutic agents, and a growing
number of biological applications have been explored. To be effective, these complexes must reach their
intended target inside the cell. Here we review the cellular accumulation of metal complexes, including
their uptake, localization, and efflux. Metal complexes are taken up inside cells through various
mechanisms, including passive diffusion and entry through organic and metal transporters. Emphasis is
placed on the methods used to examine cellular accumulation, to identify the mechanism(s) of uptake,
and to monitor possible efflux. Conjugation strategies that have been employed to improve the cellular
uptake characteristics of metal complexes are also described.
Introduction
Transition metal complexes are appealing candidates in the search
for new diagnostic and therapeutic agents. They represent a
uniquely modular system, wherein the metal center holds its
ligands in a precisely defined three-dimensional structure. These
ligands can be varied relatively easily, in order to change the
characteristics of the complex in either subtle or dramatic fashion.
Transition metal complexes also offer rich photophysical and
photochemical properties, expanding their utility beyond chemical
recognition.
Biological applications of transition metal complexes are in-
creasingly being explored.1-5 Tobe effective, these compoundsmust
reach the desired location inside the cell. There are several routes
across the cell membrane, the identity of which affects the rate of
uptake and the intracellular distribution. Also of interest is the
possibility of export by the multidrug efflux pumps, such as Pgp
and MRP1, which recognize a multitude of structurally diverse
substrates.
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The current understanding of the cellular processing of tran-
sition metal complexes, outside of cisplatin, is relatively lim-
ited, though it continues to expand. The diversity in structure
among metal complexes is at least as great as that for organic
molecules. Therefore, one can expect the same diversity of uptake
mechanisms and intracellular fate that has been characterized for
organic drugs. Indeed, as we review here, this supposition holds
true.
Methods to examine cellular accumulation
Metal complexes for diagnostic applications are frequently lumi-
nescent, allowing ready characterization of their uptake character-
istics. They can be examined by fluorometry, confocal microscopy6
and flow cytometry.7,8 For non-luminescent complexes, induc-
tively coupled plasma mass spectrometry (ICP-MS),9,10 atomic
absorption spectroscopy (AAS),11 and UV-visible absorption
spectroscopy12 are used. Analysis of exogenous transition metal
complexes by ICP-MS or AAS is greatly enabled by the fact that
no background exists within the cell. We have taken advantage of
this within our own laboratory to study non-luminescent rhodium
complexes.
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While ICP-MS and AAS represent very sensitive methods to
assay for metal content, these assays cannot be accomplished
with monitoring in real time. Cell lysates are instead prepared
from cells that have been incubated with metal complex, prior to
assay for metal uptake. When adherent cells are used, they are
either detached from the culture dish and then lysed, or lysed
directly in the dish. Alternatively, the cells can be detached and
treated with complex in suspension, though in this case, the cells
are not in their normal growing environment. This cell lysate is
analytically diluted, and the amount of metal in the solution is
quantified. Amounts are typically reported versus cell number or
total protein concentration. Independent of the quantification
technique, attention must be paid to certain steps to ensure
accurate results. Egger and colleagues have found that adsorption
to the culture plates and sample storage conditions prior to
analysis significantly influence recovery of the metal.9 Factors
affecting adsorption include concentration of the complex, the
amount of protein in the medium, the duration of contact of
protein-containing medium before treatment with complex, and
the lipophilicity of the complex. Adsorption-related artifacts are
particularly an issue when lysis is performed directly in the culture
dishes. To correct for these effects, adsorption blanks of cell-
free samples treated with metal complex should be performed.
A second major issue is the time that the sample is stored prior
to measurement, as the recovery of analyte decreases with time.
Consequently, samples should be quantified immediately after
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preparation. When these considerations are taken into account,
reliable measurements of metal complex uptake can be performed.
The cellular uptake of luminescent metal complexes is primarily
examined using two complementary methods, flow cytometry
and confocal microscopy; fluorometry of cell lysates can also be
performed. For flow cytometry, cells are detached from culture
either before or after incubation with the metal complex to
produce a cell suspension. Untreated cells are used for as a
control for autofluorescence. To exclude dead cells from analysis, a
membrane-impermeable dead cell dye, such as propidium iodide,
can be added.13 The cells are inspected individually as they pass
single file through the laser beam(s) and the instrument records
their light scatter and luminescence (Fig. 1). Optical band pass
filters separately collect the emission from multiple fluorophores.
The result is a distribution of luminescence for the cell population,
which can be depicted as a histogram of the number of cells versus
luminescence intensity. The luminescence intensity of different
cell populations, e.g. treated with different complexes or different
incubation conditions, is easily compared.
Fig. 1 Flow cytometry analysis of cellular uptake. (A) The sample
stream containing the cells are injected into a flowing stream of sheath
fluid, which focuses the sample stream to roughly one cell in diameter.
The luminescence and light scatter are recorded for each cell as it
passes through the laser beam. (B) Histograms are shown representing
cells treated with different metal complexes. Untreated cells display
some background luminescence. Complexes with greater uptake exhibit
increased luminescence intensity.
Flow cytometry is faster and less labor intensive than prepara-
tion of samples for ICP-MS, but still does not allow real-time
monitoring. It also provides a distribution of cellular uptake,
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rather than only themean uptake of all the cells. Samples prepared
for flow cytometry will have the same adsorption issues described
above, though theymay be less significant, as the cells are detached
from the culture dish after incubation with the metal compound,
rather than lysed in the dish, or incubated in suspension following
detachment. Flow cytometry distinguishes live from dead cells by
uptake of a dead cell dye, whereas with ICP-MS, dead cells are
eliminated from analysis if they have lost adherence to the culture
dish and are washed away before the lysis step. Both techniques
have their purpose, as ICP-MSprovides absolute values for uptake,
while flow cytometry is limited to luminescent compounds and is
better suited for comparing the amount of uptake under different
conditions.
Flowcytometry andanalysis of cell lysates by ICP-MSandother
methods only provide a measurement of the total amount of metal
complex associated with the cell; they do not distinguish between
membrane-bound and intracellular material. Localization is dif-
ficult to discern by these techniques, where cellular components,
such as nuclei, must be physically isolated before themetal content
can be determined.14
Confocal microscopy, on the other hand, reveals the spatial
distribution of luminescent metal complexes inside the cell. Co-
staining with organelle dyes can be performed to further pinpoint
their intracellular location. For non-luminescent complexes, dis-
placement of dyes can provide indirect evidence of localization.
For example, competitive displacement of the DNA stain Hoechst
33258 has been used to demonstrate nuclear accumulation.15 In
fact confocal microscopy even offers the opportunity of real-time
monitoring of luminescent complexes in situ. Another notable
advantage of microscopy over ICP-MS is that lesser amounts
of metal complex are typically required, as the incubations can
be performed in small wells (e.g. those of a 96-well plate).
To acquire better quality images, adherent cells are preferable
over suspension cells, and the cells should not be confluent.
Importantly, cells should be imaged live rather than fixed, as
fixation can cause artifactual redistribution of compounds.16 In
all uptake experiments, attention should be paid to the number of
cells incubatedwith themetal complex, since the amount of uptake
may be dependent on it. This has been shown to be the case for cell-
penetrating peptides (CPP).17 The merits of the different methods
for measuring cellular accumulation are summarized in Table 1.
Finally, in the absence of direct studies of uptake, biological
activity may serve as a proxy. Here, of course, the lack of activity
does not necessarily indicate the lack of cellular accumulation.
However, biological read-outs of cytotoxicity, cellular prolifera-
tion, or other biochemical processes can be performed sensitively,
and necessarily reflect uptake of the complex.
Identification of the uptake mechanism
Understanding how metal-based probes and therapeutics gain
entry to the cell is important for their practical development, as
the import mechanism has implications for cell-type specificity,
the rate of uptake, and their intracellular fate. The pathways
into the cell include passive diffusion, transport proteins, and
endocytosis (Fig. 2). Passive diffusion involves the movement
of molecules directly through the lipid bilayer down their con-
centration gradient. Transport proteins each move a particular
class of cargo, and expression varies by tissue type. They can be
energy-independent, as for channels and passive carriers, or be
energy-dependent, as for ATP-powered pumps. Endocytosis is the
uptake of macromolecules and solutes by vesicles derived from
the plasma membrane. Diverse techniques including chemical,
molecular biology, and imaging tools can be employed to reveal
the mechanism of uptake.
One clear dividing line between differentmechanisms is whether
uptake requires energy, as for endocytosis and active transport
proteins, or is energy-independent, as is the case for passive
diffusion through the membrane and diffusion facilitated by
channels and carriers. Processes that require energy can be
blocked by incubating cells at low temperature (4 ◦C) or by ATP-
depletion with metabolic inhibitors, such as 2-deoxyglucose (com-
petitively inhibits glycolysis)18 and oligomycin (blocks oxidative
phosphorylation).19
Passive diffusion is the pathway least susceptible to modulation.
Uptake is energy-independent, is not saturable, and cannot
be hindered by structural analogues. However, changes in the
membrane fluidity, such as by cholesterol depletion or low
temperature, can alter uptake. Cholesterol can be extracted from
the plasma membrane using methyl-b-cyclodextrin.20,21 Also, the
plasma membranes of most cells exhibit a membrane potential,
with the inside of the cell negative with respect to the outside,
which can serve as a driving force for the entry of positively
charged compounds. In animal cells, the membrane potential
depends primarily on the potassium concentration gradient.
Consequently, the potential can be reduced by incubating the
Table 1 Comparison of methods for examining cellular accumulation
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Fig. 2 Routes into the cell. Passive diffusion, facilitated diffusion, active protein transporters, and several endocytic pathways are illustrated. Inhibitors
and activators of each pathway are shown.
cells in a buffer with a potassium concentration equivalent to that
found intracellularly. Gramicidin, a pore-forming peptide, also
reduces the membrane potential by facilitating K+ equilibration.22
Conversely, hyperpolarization can be achieved using valinomycin,
a cyclic peptide that selectively shuttles potassium ions across the
membrane.22 Cationic dyes such as 3,3¢-dihexyloxacarbocyanine
are useful for verifying changes in the membrane potential.23 One
should note that maintenance of the membrane potential requires
ATP, and experiments involving metabolic inhibition may also
affect the membrane potential, depending on the severity and
duration of the metabolic blockade.
Protein-mediated transport can be active or passive. Exam-
ples of passive carriers include the organic cation transporters
(OCTs).24 Other proteins couple downhill transport of an ion to the
uphill movement, such as the peptide transporters (PEPTs),25 or
take advantage of ATP hydrolysis. In contrast to passive diffusion,
uptake is susceptible to inhibitors and can saturate. To study
transport proteins, known inhibitors of suspected transporters
can be used, and then cells observed for decreased uptake of
the test compound. Alternatively, a specific transporter can be
overexpressed, and the level of uptake compared to cells with low
transporter expression.
Endocytosis encompasses several distinct pathways, which
can be divided into two broad categories, phagocytosis and
pinocytosis. Phagocytosis, the uptake of large particles, occurs
only in specialized cells. Pinocytosis occurs in all cells by at
least four distinct pathways: macropinocytosis, clathrin-mediated
endocytosis, caveolae-dependent endocytosis, and clathrin- and
caveolin-independent mechanisms.26,27 Uptake can be fluid-phase,
adsorptive (nonspecific binding of solutes to the cell membrane),
or receptor-mediated.
There are pharmacological treatments that can aid in distin-
guishing endocytic pathways, though the degree of their specificity
varies substantially. Clathrin-mediated endocytosis is inhibited by
hypertonic sucrose, potassium depletion, cytosolic acidification,
chlorpromazine, monodansylcadaverine (MDC), and phenylar-
sine oxide. As all of these inhibitors have been shown to block
uptake of fluid phase markers, they cannot be used to distinguish
between clathrin-mediated endocytosis and macropinocytosis. Of
these techniques, potassiumdepletion, chlorpromazine, andMDC
appear to have the fewest side-effects.28
Most inhibitors of caveolae-mediated endocytosis target choles-
terol. Methyl-b-cyclodextrin (MbCD) forms soluble inclusion
complexes with cholesterol, depleting it from the membrane.
However, MbCD can also inhibit clathrin-mediated endocytosis
and macropinocytosis, particularly at higher concentrations.29,30
Filipin and nystatin sequester cholesterol in the formofmembrane
aggregates. These drugs disrupt caveolar structure and function
but do not seem to impair clathrin-mediated endocytosis or
macropinocytosis.31,32 Another approach to deplete cholesterol
uses cholesterol oxidase to convert cholesterol into 4-cholesten-
3-one; this method has been shown to attenuate internalization of
caveolae ligands.33
For inhibition of macropinocytosis, drugs targeting actin poly-
merization, phosphoinositide metabolism, and sodium-proton
exchange have been used. Agents that disrupt actin, such
as cytochalasin D, are not specific for macropinocytosis as
actin is required in multiple endocytic pathways.34 Wortman-
nin, a phosphoinositide 3-kinase (PI3K) inhibitor, blocks not
only macropinocytosis and phagocytosis but also clathrin- and
caveolae-mediated pathways.35,36 Amiloride and its derivatives,
5-(N-ethyl-N-isopropyl) amiloride (EIPA) and dimethyl amiloride
(DMA), inhibitors of the Na+/H+ exchanger, block macropinocy-
tosis and phagocytosis.37 Notably, the amilorides appear to
have fewer side effects than the other available inhibitors
of macropinocytosis. Stimulation of macropinocytosis can be
achieved using phorbol esters38 and diacylglycerols.39 Therefore,
both suppression with amiloride and an increased response with
the aforementioned stimulants can be used to definemacropinocy-
tosis.
The tools of molecular biology allow further characterization
of the endocytic mechanism through identification of relevant
proteins. The machinery driving clathrin-mediated endocytosis
includes the clathrin triskelion, composed of three clathrin heavy
chains and three light chains, which assemble into a polygonal
lattice that molds the plasma membrane into a coated pit.27
Clathrin function can be modulated by overexpression of the
heavy chain hub domain, which has a dominant negative effect
on clathrin coat assembly, or by downregulation of clathrin heavy
chain expression with siRNA40 Caveolae contain members of the
caveolin protein family, and they can be disrupted by overex-
pression of dominant-negative caveolin mutants and knockout
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of caveolin genes.27 A critical regulator of clathrin-mediated,
caveolin-mediated and some clathrin- and caveolae-independent
pathways is dynamin.41 The recruitment and assembly of dynamin
at the neck of forming vesicles catalyzes their fission. Dominant-
negative dynamin mutants can be used to study its involvement as
well as the small molecule inhibitor dynasore.42,43 As the mode of
endocytosis is narrowed, the involvement of other proteins can be
studied in a similar manner.
Colocalization of a luminescent metal complex with an
endocytic marker supplies further evidence of entry via
endocytosis. Numerous fluorescent tracers are commercially
available.44 Clathrin-mediated endocytosis can be followed using
fluorescently-tagged transferrin or low density lipoprotein (LDL)
particles.45 After transferrin binds to its receptor on the plasma
membrane, it is internalized in clathrin-coated vesicles, traffics
through early and recycling endosomes, then returns to the
plasma membrane. Similarly, LDL is recognized by the LDL
receptor and enters by clathrin-mediated endocytosis. The LDL
particle dissociates from its receptor in late endosomes, allowing
its receptor to recycle back to the cell surface while LDL is
transported into lysosomes.46 Labeled dextran is a fluid phase
marker often used to follow macropinocytosis, though fluid phase
markers have access to other types of vesicles. Cholera toxin B
subunit has been used to track caveolae-mediated endocytosis,
but it can enter by multiple mechanisms depending on the cell
type, including clathrin-dependent and caveolae- and clathrin-
independent endocytosis.47-50 The fluorescent glycosphingolipid
analogue, BODIPY-LacCer, has also been used to track caveolae
internalization.51
Routes for cell entry by metal complexes
How do metal complexes exploit the various pathways into the
cell? Thoughmetal complexes are being investigated as probes and
therapeutics, there are a relatively few studies on their mechanism
of uptake. The cellular accumulation of cisplatin has received the
most scrutiny andhas been recently reviewed.52 Platinumdrugs can
enter the cell by passive diffusion, by organic cation transporters,
by the copper transporter Ctr1, and possibly by endocytosis.
The mechanism of uptake for several luminescent Eu(III) and
Tb(III) complexes has been characterized by Parker and coworkers
(Fig. 3).53 These complexes enter cells bymacropinocytosis andnot
via clathrin-mediated endocytosis or caveolae. Both wortmannin
and amiloride suppress their uptake, while a phorbol ester and a
diacylglycerol enhance uptake. The complexes also colocalize with
fluorescein-labeled dextran.
Studies by Lo and colleagues on bis(cyclometalated) iridium(III)
polypyridine complexes suggest their entry by more than one
mechanism.54 The uptake of [Ir(ppy)2(bpyC4)]+, where ppy =
2-phenylpyridine and bpyC4 = 4,4¢-bis(n-butyl-aminocarbonyl)-
2,2¢-bipyridine (Fig. 3), into cytoplasmic foci was diminished at
4 ◦C, while the diffuse cytoplasmic staining was maintained. A
similar effect was observed upon treatment with the colchicine,
which interferes with microtubule assembly and inhibits endocy-
tosis. Thus, uptake occurs both by an energy-dependent pathway
(possibly endocytosis) and an energy-independent pathway.
For some Ru(III) complexes, cellular entry is mediated by the
iron transport protein transferrin. The drug candidate KP1019,
indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
(Fig. 3), binds transferrin with displacement of a chloride ligand,
then enters the cell by clathrin-mediated endocytosis.55 Transferrin
can bind two ruthenium moieties, one at each iron binding site,
but this results in lower accumulation of ruthenium in the cell. Oc-
cupation of both iron binding sites by ruthenium probably causes
a structural change in the protein that prevents it from binding
to its receptor. In contrast, transferrin equilibrated with iron
before binding of one ruthenium moiety results in substantially
increased uptake. Following cellular entry, transferrin localizes in
endosomes; therefore the release of the ruthenium complex from
transferrin and subsequent endosomal escape likely occurs.
Fig. 3 Metal complexes whose cellular accumulation have been explored. Top row: cisplatin, a Eu(III) complex that enters cells by macropinocytosis,
an Ir(III) polypyridine complex, the drug candidate KP1019, and a Ru(II) arene complex. Bottom row: a Au(I) phosphine complex that accumulates
in mitochondria, the radiopharmaceutical [99mTc]Sestamibi, a Ru(II) dipyridophenazine complex, a Eu(III) complex that stains nucleoli, and a Rh(III)
metalloinsertor that binds DNA mismatches.
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Metal complexes that are lipophilic cationsmaypassively diffuse
across the plasma membrane in response to the membrane po-
tential. The imaging agent hexakis (2-methoxyisobutyl isonitrile)
technetium(I), known as [99mTc]Sestamibi (Fig. 3), accumulates
inside cells driven by both the plasma and mitochondrial mem-
brane potentials.56 Uptake is reduced by depolarization of the
plasma membrane with high potassium buffer and depolarization
of the mitochondrial membranes with the proton ionophores 2,4-
dinitrophenol and carbonyl cyanide m-chlorophenylhydrazone.
Similarly, a Ru(II) complex containing the lipophilic 4,7-diphenyl-
1,10-phenanthroline ligand (Fig. 3) enters by passive diffusion in
a membrane-potential dependent manner.57
Localization
Nuclear targeting
Cellular accumulation alone is insufficient to enable activity;
any potential therapeutic agent must also be able to reach its
target within the cell. As many metal complexes are targeted to
DNA, they must furthermore gain nuclear access, which is tightly
regulated by the nuclear pore complex (NPC).58 In addition to
actively transporting cargo such as RNAs and large proteins, the
NPC also facilitates the diffusion of small molecules, ions, and
proteins.Although some fractionof the cytoplasmic concentration
of a metal complex will certainly diffuse passively through the
NPC, the efficiency of nuclear entry warrants consideration
beyond this supposition. It is reasonable to assume that efficient
nuclear localization would reduce off-target effects. Conversely,
poor nuclear localization would pose a serious obstacle to the
utility of any DNA-targeted agent.
To this end, Parker and coworkers have developed a class of
luminescent probes based on cationic lanthanide complexes.59
The initial europium and terbium complexes were shown to
reversibly localize within the nucleus above a 1 mM concentration
threshold; subsequently, a europium complex has been developed
that selectively targets nucleoli at lower concentrations.60 The long
lifetime, large Stokes shift, and relatively high quantum yield of
this complex (shown in Fig. 3) make it an interesting tool for the
further study of nucleoli, whose role is not yet fully understood.61
Seymour’s group exploited the intrinsic fluorescence of zinc
bis(thiosemicarbazone) (TSC) complexes to study their cel-
lular uptake and localization through confocal fluorescent
microscopy.62 Their work clearly showed that nuclear uptake
varied with subtle structural differences in the complex as well as
with cell line. In addition to their inherent potential as antitumor
agents, these zinc TSC complexes may also provide insight into
the uptake of analogous copper complexes, as the two classes are
structurally very similar.
In our laboratory, we have used luminescent ruthenium ana-
logues to study cellular uptake and localization.8,57 Given the
brightness and robust characteristics of polypyridyl complexes of
Ru(II), we could make systematic changes in the ligand set and
examine how uptake varied using flow cytometry and confocal
microscopy. We observed, for example, that hydrophobicity of
the complex was more of a driver for cell entry than size;
[Ru(DIP)2dppz]2+ is taken up more readily inside cells versus
[Ru(bpy)2dppz]2+ despite its large bulk (20.4 A˚ in diameter)
(Fig. 4).
Fig. 4 Cellular uptake of dipyridophenazine (dppz) complexes of Ru(II).
The lipophilic complex [Ru(DIP)2dppz]2+ is observed inside HeLa cells at
lower incubation concentrations and shorter times (top, 5 mM for 2 h) than
[Ru(bpy)2dppz]2+ (bottom, 20 mM for 72 h). Structures of complexes are
shown at left. Scale bars are 10 mm.
Importantly, the intrinsic luminescence of the ruthenium com-
plex was also critical in revealing that fluorescent tagging with an
organic fluorophore could alter subcellular localization, yielding
nuclear accumulation that was not seen in the absence of the
fluorescent tag.63 This result served as a striking example of
the pitfalls of fluorescent labeling, how the fluorophore may
provide more than just a “label”. This result also underscored
the advantages of utilizing luminescent metal complexes that do
require an extra “label”.
For non-luminescent complexes, ICP-MS and AAS can also
yield semi-quantitative information about relative metal levels in
isolated nuclear or mitochondrial fractions. These techniques are
particularly amenable to analysis of exogenous transition metals.
In addition, measurements of biological activity have served
as a proxy for uptake for a class of rhodium metalloinsertors
developed within our group (Fig. 3).8,64 HCT116 +ch3/+ch2
cells were treated with [Rh(L)2chrysi]3+ complexes where chrysi =
chrysenequinone and L = (NH3)2, 2,2¢-bipyridine (bpy), 2,2¢-
dipyridylamine (HDPA), 1,10-phenanthroline (phen), or 4,7-
diphenyl-1,10-phenanthroline (DIP) for various incubation times.
Optimal activity for the DIP complex is observed with 12 h
incubation and a lower concentration than the other complexes, as
would be expected from confocal microscopy and flow cytometry
studies of [Ru(L)2dppz]2+ analogues. The 48–72 h required for
optimal activity of the remaining complexes also correlates
well with ruthenium uptake times. Unexpectedly, the HDPA
complex exhibits activity after only a short 12 h incubation,
suggesting accelerated uptake relative to that expected based upon
hydrophobicity; subsequent ICP-MSuptake assays of the rhodium
complexes confirms that the HDPA ligand modestly improves
cellular uptake.
Mitochondrial targeting
Mitochondria have emerged as an interesting alternative target
for many applications.65,66 Mitochondria use the energy released
by the oxidation of substrates such as glucose to establish a
proton gradient across their innermembrane. This proton gradient
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drives ATP synthetase, which produces the majority of the ATP
required for active processes within the cell. Since mitochondria
maintain their own genome, which codes for the enzymes of the
electron transport chain, it is possible that DNA-targeting metal
complexes could effectively compromise mitochondrial function.
Thus mitochondrial targeting also presents an interesting strategy
for new chemotherapies.
Indeed, anymetal complex that disruptsmitochondrial function
could hold potential as a chemotherapeutic agent, regardless of
whether or not the complex targets DNA. To this end, Berners-
Price and colleagues have developed gold(I) phosphine complexes
that accumulate in mitochondria and trigger apoptosis through
the caspase-3 and caspase-9 dependent mitochondrial pathway
(Fig. 3).67 These complexes were shown to have selective activity
in breast cancer cells at submicromolar concentrations. This
approach has been expanded to include silver(I) phosphine com-
plexes that also accumulate in the mitochondria in a membrane
potential-dependent fashion and show cytotoxicities that correlate
with their lipophilicities.68
Compared to nuclear targeting, mitochondrial targeting is rel-
atively facile, with a clearly understood chemical basis; lipophilic
cations have been shown to accumulate in mitochondria due
to the negative potential difference across the mitochondrial
membrane.69,70 Furthermore, carcinoma cells have been shown to
have higher plasma and/or mitochondrial membrane potentials,
providing ameans of selectively targeting them.71,72 The reasons for
the increased membrane potential have yet to be fully understood,
but work in this area holds the promise of further increasing
selectivity.
In addition to the use of lipophilic cations as anticancer agents,
Murphy and colleagues have employed triphenylphosphonium
(TPP) salts as delivery vehicles for several other applications.73,74
As a potential treatment for a broad range of diseases associated
with oxidative damage in the mitochondria, an antioxidant based
on the activemoiety of vitaminEwas conjugated to aTPP cation.75
The resulting conjugate was concentrated in the mitochondria by
the membrane potential, reaching levels approximately 80-fold
greater than those of vitamin E alone. Although most of the
work in mitochondrial targeting to date has employed organic
cations, organometallic ions potentially could deliver cargo to the
mitochondria in a similar manner.
Efflux
Efflux mediated by protein export pumps is a major contributor to
drug resistance in cancer cells, in which therapeutics are removed
before they can exert their intended effect. Efflux transport
proteins are also expressed in normal tissues, where they limit
the absorption (intestine), block the distribution (blood-brain
barrier), and facilitate the elimination (kidney and liver) of
drugs. In human cancers, the major drug efflux pumps belong
to the ATP-binding cassette (ABC) protein family. These include
P-glycoprotein (Pgp, MDR1, ABCB1), members of the multidrug
resistance-associated protein family (MRP1-9, ABCC1-9), and
ABCG2 (MXR, BCRP). These proteins transport a remarkable
range of substrates, with their transport profiles overlapping to
some extent. Compounds recognized by Pgp are often large, am-
phipathic molecules that are neutral or have a net positive charge,
though not all Pgp substrates conform to this generalization.76
The MRP family transports neutral and anionic drugs, as well
as glutathione, glucuronate, and sulfate conjugates.77,78 ABCG2
also has broad substrate specificity and is able to transport both
positively and negatively charged compounds.79
Several in vitro systems can be used to assess whether a
compound is susceptible to transport by an efflux pump. They
measure cytotoxicity, accumulation/efflux, transport, or ATPase
activity. These methods are summarized below, and further details
are available in recent reviews.80,81
For drugs that show antiproliferative activity, cytotoxicity
(resistance) assays are commonly used. Typically, cytotoxicity is
expressed as the IC50 value, the concentration of drug required
to kill half of the cells, calculated from the dose-response curve.
To study protein-mediated export, cell survival following drug
treatment is compared between parental cells and cells that
overexpress a particular efflux protein. Transported compounds
should exhibit decreased toxicity, and efflux pump inhibitors
should restore activity in transporter-expressing cells. Numerous
inhibitors are available for the major ABC efflux pumps.82
Accumulation assays (vide supra) offer a more direct measure-
ment of efflux transporter activity. They can be performed on
cells or membrane vesicle preparations. Similar to the resistance
assays, cell lines with differential transporter expression are used.
If a compound is an efflux pump substrate, accumulation will be
lower in the transporter-expressing cell line versus the parental
line, and transporter inhibitors should increase accumulation. For
compounds lacking an easy handle for monitoring accumulation,
indirect competition methods using a fluorescent reference sub-
strate are an option. Such probes include calcein-AM for Pgp and
MRP1andHoechst 33342 forABCG2.76 Here, the effect of the test
compound on the accumulation of the fluorescent dye is observed.
This assay can show if a compound interacts with the transporter,
but it does not distinguish between substrates and inhibitors.
Alternatively, accumulation assays can be performed using inside-
out membrane vesicles. In this case, the transporter pumps the test
compound into the vesicle. Inhibition of the transporters would
decrease accumulation of the compound in the vesicles. Inside-out
vesicles each containing different efflux transporters are available
from several commercial suppliers.
Measurement of transcellular transport, the passage of
molecules across a cell layer, is another method for studying
export. Polarized cells that express efflux transporters are grown
to confluence on a permeable surface (a transwell). The cells
must form tight extracellular junctions, such that movement of
the test compound from one side of the monolayer to the other
can only occur by passage through the cells. The transporters
may be localized on the apical side of the polarized monolayer,
such as for Pgp and ABCG2, or the basolateral side, the case for
MRP1. Apical transporters will increase movement in the basal to
apical direction; basal transporters will do the opposite. The test
compound is added to one side of the cell monolayer, and over
time its concentrations in the basal and apical compartments are
measured. Transported compounds will exhibit a directional bias
that can be altered by inhibition of the efflux transporter.
ABC efflux transporters are powered by ATP hydrolysis, and
the presence of substrates usually stimulates this process. Hence,
quantificationofATPase activity is anothermethod for identifying
transported compounds.83 For this assay, cell membrane prepa-
rations containing the transporter are incubated with ATP and
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the test compound. ATP hydrolysis releases inorganic phosphate,
which can be detected by various analytical methods, such as
reaction with a colorimetric indicator.84 ATP hydrolysis indicates
that the test compound affects ATPase activity, but does not
directly demonstrate efflux, and slowly transported substratesmay
not induce detectable ATPase activity.
Many metal complexes have been shown to be actively exported
from cells. [99mTc]Sestamibi (Fig. 3), a radiopharmaceutical used
for imaging the blood flowof the heart, was the firstmetal complex
shown to be transported out of the cell by Pgp.85 Similar to
many other Pgp substrates, the complex is positively charged and
hydrophobic. In cells expressing Pgp, the net accumulation of the
[99mTc]Sestamibi is inversely proportional to the amount of Pgp
expression, and export could be reversed by Pgp inhibitors such
as verapamil, cyclosporinA, andquinidine. [99mTc]Sestamibi is also
recognized by MRP1.86,87 Numerous other technetium complexes
have been characterized regarding their Pgp transport activity, due
to their promise in diagnostic imaging of Pgp-mediated transport
in tumors.88
The cellular efflux of cisplatin is mediated by multiple
mechanisms.52,89 Evidence suggests that the copper transporters
ATP7A and ATP7B, which are responsible for the removal
of excess copper ions from the cell, play a role in cisplatin
export. Their expression can reduce cisplatin accumulation and/or
efficacy, though not all cisplatin-resistant cell lines show increased
expression. TheMRP transportersmay also export cisplatin, most
likely as a glutathione conjugate. Pt(II) and glutathione (GSH)
form a stable Pt(GS)2 complex, in which glutathione chelates Pt
via cysteinyl sulfur and nitrogen atoms.90 Some cell lines with
elevated MRP2 levels show increased cisplatin resistance, reduced
accumulation, and decreasedDNAplatination. Cisplatin does not
appear to be a Pgp substrate.91,92
Theactive export of two classes of rutheniumcomplexes has also
been examined. The Ru(III) complex KP1019 (Fig. 3) is a substrate
and inhibitor of Pgp.93 Pgp expression reduced KP1019 cytotoxic-
ity, and this effect could be reversed byPgp inhibitors.KP1019 also
restored accumulation of rhodamine 123, a fluorescent substrate
of Pgp, in cells overexpresing P-glycoprotein. In contrast, activity
of the complex was not diminished by overexpression of MRP1
or BCRP. Certain Ru(II) arene complexes may also be effluxed by
Pgp (an example is shown in Fig. 3).94 A series of Ru(II) complexes
exhibited reduced toxicity in a multi-drug resistant cell line, which
has elevated levels of both Pgp and MRP2. Verapamil, a Pgp
inhibitor, restored sensitivity to one of these Ru(II) complexes. In
common with many other Pgp substrates, these complexes are
hydrophobic and positively charged.
Conjugates
The most widely used strategy to accelerate the uptake or to
increase the accumulation of metal complexes within the cell
is to attach a biomolecule covalently that directs trafficking of
the conjugated complex. Synthetic polymers and several different
types of biomolecules have been utilized to this end, including
peptides, B vitamins, carbohydrates, and hormones. Cisplatin and
its derivatives are by far themost popular choice of cargo (Table 2).
Many groups have used short peptide sequences to direct uptake
of a bioinorganic conjugate by targeting a particular receptor
or cell compartment. Lippard and coworkers have combined
platinum(IV) complexes with peptides containing an RGD or
NGR motif.95 These sequences serve as substrates of the integrins
an/b3 and an/b5 or aminopeptidase N, respectively, which are
overexpressed during tumor-associated angiogenesis, providing an
avenue to selectively target cancerous tissue. Indeed, conjugates
Table 2 Biocarriers and their metal cargoes
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of the substrate peptides were found to have roughly ten-fold
greater activity than either conjugates of nonspecific sequences or
the functionalized platinum(IV) complex without any conjugated
peptide. No activity was observed for the peptide sequences
themselves. Nils Metzler-Nolte and coworkers have synthesized
and extensively characterized a wide variety of bioconjugates of
amino acids, peptides, and peptide nucleic acids with various
transition metals, including iron, copper, zinc, and cobalt with
the intention of targeting specific organelles.96,97 Their work ex-
amines metallocene and carbonyl alkyne complexes, and includes
fluorescencemicroscopy and cytotoxicity studies that demonstrate
the potential of a class of ferrocene-peptide conjugates to act as
anti-microbial agents.98,99
Kelley and coworkers have shown that rationally designed
peptide sequences containing cationic and lipophilic residues, e.g.
FrFKFrFK (lower case denotes the D-isomer, used for enhanced
biostability), can effectively and specifically deliver cargo to the
mitochondria, but these sequences have not been used with
metal complexes.100 This work is in accordance with findings
that delocalized lipophilic cations accumulate in mitochondria
(see Localization). While similar efforts to access selectively each
organelle will undoubtedly remain a sought-after goal for those
studying cellular uptake, the nucleus is by far themost prominently
studied and therapeutically relevant target of peptide localization
sequences and their conjugates.
To that end, short peptide sequences rich in positively charged
residues such as arginine or lysine have been shown to function
either as cell-penetrating peptides (CPPs), nuclear localization
sequences (NLSs), or both. CPPs promote cellular uptake by
translocation across the cell membrane or by endocytosis, whereas
NLSs promote active transport through the nuclear pore complex.
Early demonstrations of peptide-directed nuclear import involved
the sequence PKKKRKV, from simian virus SV40 large tumor
antigen, and the sequence GRKKRRQRRRAP, from the HIV-
1 Tat peptide, which has also been shown to mediate cellular
uptake.101-104 Since then, several other sequences, including syn-
thetic sequences such as octaarginine, have been identified that
share similar chemical characteristics and uptake properties.104,105
In an attempt to exploit the uptake properties that these peptide
sequences confer, Vicente and coworkers conjugated photody-
namic therapy (PDT) agents based on zinc(II) phthalocyanines
to a bifunctional peptide sequence containing the Tat sequence
and the NLS from nucleoplasmin.106 The peptide conjugates were
shown to have slightly better cellular uptake and phototoxicity
profiles than the unconjugated metal complexes. Fluorescent
microscopy was performed on live HEp2 cells treated with the
conjugates; in order to examine subcellular localization, the cells
were simultaneously treated with organelle-specific fluorescent
stains such as LysoSensor and MitoTracker. Significantly, image
overlays showed that the conjugates were localizing mainly within
lysosomes, consistent with cellular entry through endocytosis and
subsequent failure to escape from the internalized endosomes.
These experiments, then, reveal an obstacle to the widespread
application of NLS peptides as delivery vehicles: endosomal
trapping.
Interestingly, the extent of cellular uptake was also shown to be
a function of the structure of the linker region; the conjugate
containing a longer polyethylene glycol (PEG) linker region
accumulated at higher levels. PEG linkers are commonly used in
conjugate development due to the pharmacological benefits that
they confer, including increased solubility and bioavailability and
reduced systemic toxicity. Gibson and coworkers also employed
PEG linkers to conjugate the anticancer agent carboplatin with
a variety of NLS peptides.107 Based on the results of confocal
microscopy studies with live M109FR cells and fluorescently
labeled conjugates, the NLS successfully promoted rapid accu-
mulation in the nucleus. However, the NLS-PEG-Pt conjugate
formed less Pt-DNA adducts and was less cytotoxic than PEG-
Pt or carboplatin alone. Gibson’s group interpreted these results
as support for the notion that carboplatin requires cytosolic
activation for its anticancer activity. Accordingly, bioconjugates
of other metal complexes that require activation might encounter
similar problems.
Within our own laboratory, octaarginine has been used to
target rhodium mismatch-recognition agents to the nucleus.
Early fluorescent microscopy experiments on live HeLa cells
were very promising, showing dramatic nuclear accumulation
at reduced incubation times.108 However, further investigations
with fluorescent ruthenium complexes revealed yet another pitfall
in conjugate development. The intrinsic luminescence of the
ruthenium complexes allowed us to examine the distribution of the
conjugates in the absence of a fluorescent organic tag, revealing
that the organic fluorophore itself redirected the rhodium-peptide
conjugate, which otherwise would not accumulate in the nucleus
under the same conditions.63 This further emphasized that the
uptake, and presumably inhibitory, properties of any conjugate
are extremely sensitive to even subtle structural changes, such as
addition of a fluorophore.
Metzler-Nolte and co-workers addressed this issue very ele-
gantly by using atomic absorption spectroscopy (AAS) to study
the cellular and nuclear uptake of cobalt bis(picolyl)amine com-
plexes in live HT29 cells.109 This method allowed for the direct
detection of unlabeled metal complex, eliminating any possibility
of redirection; as mentioned in this report, inductively-coupled
plasma mass spectrometry (ICP-MS) provides another alternative
for direct detection. The complexes were conjugatedwith the SV40
antigen NLS, a PNA sequence (TGTTATCC), or both. Both
the NLS and the PNA sequence were found to increase nuclear
levels of cobalt, although the PNA sequence was slightly more
effective in this case. The group had previously used the SV40
NLS to direct a fluorescently labeled cobaltocenium conjugate to
the nucleus, as shown by fluorescent microscopy.110 Co-staining
experiments also showed localization within the endosomes,
consistent with endocytic entry into the cell. More recently, the
group systematically investigated the cellular and nuclear uptake
of an expanded class of conjugates, containing different metal
complexes and peptide sequences, in the HepG2 cell line.111
Again, fluorescent microscopy and co-staining experiments were
performed on live cells. Interestingly, scrambled versions of the
SV40 NLS did not afford rapid cellular and nuclear uptake. In
addition, the group has utilized the enkephalin peptide (YGGFL)
as a vector for a cobalt carbonyl alkyne complex, although the
cellular uptake properties of the conjugate were not determined.112
The SV40 NLS has also been used to direct a trifunctional
conjugate to the nucleus of mouse melanoma cells.113 The DNA
intercalator pyrene was linked to an aliphatic triamine ligand
which chelates either technetium-99m, an Auger electron emitter
that exhibits strong radiotoxicity when in close contact withDNA,
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or rhenium, which provides a nonradioactive analogue. Appeal-
ingly, the pyrene moiety provided an intrinsic fluorescence for all
conjugates. The SV40 NLS was used to complete the trifunctional
conjugate and direct it to the nucleus. Both fluorescentmicroscopy
and radiometry of extracts from 99mTc-treated cells confirmed that
the conjugate accumulated in the nucleus, leading to radiotoxicity
that was absent in the Re-treated cells.
Access to the nucleus for contrast agents such as gadolinium
would also unlock a plethora of new applications in diagnostic
imaging. With this goal, a combination of the SV40 and the acute
lymphatic leukemia-1 (RKRKRK) NLS sequences was used to
develop a gadolinium contrast agent that was found to localize
in the nuclei of a human glioma xenograft in nude mice.114 Also
technetium-99mand rhenium conjugateswith theTat peptide have
been developed for diagnostic and radiotherapeutic applications,
using radiometric and fluorescent microscopy techniques to
study the effects of peptide chirality and sequence on cellular
uptake.115-117
Although peptides are the most common biomolecular carrier
for metal complexes, there are many others. Alberto’s group is
also developing conjugates to use vitamin B12 as a vehicle for
platinum(II) complexes.118 Moreover, even dextran and galactose
conjugates have been harnassed to deliver platinum prodrugs.119-121
Hormone conjugates have garnered more attention due to the
promise of tissue specificity. The first hormone conjugates came
from Schally’s laboratory, where a variety of cytotoxic agents,
including a cisplatin-like complex, were linked with luteinizing
hormone-releasing hormone in 1992.122 More recently, estrogen
conjugates in particular have been developed as a means of
targeting breast cancer cells, which express estrogen receptors.
Hannon and coworkers have created and extensively characterized
an estrogen-platinum complex that binds serum albumin and
DNA.123 They demonstrated that it was capable of binding the
estrogen receptor in isogenic MCF-7 ER+/ER- cell lines, human
breast adenocarcinoma lines that either express or do not express
the nuclear estrogen receptor, by a competitive radioligandbinding
assay.124 Schobert, Berhardt, and Hammond have collaborated
to develop cisplatin conjugates of estradiol and various other
steroidal alcohols and have shown that these conjugates bind sex
hormone binding globulin (SHBG), a transport protein for estro-
gens and androgens, and the nuclear estrogen receptor (ERa).125
Curiously, the complex that displayed the greatest cytotoxicity
failed to distort plasmid DNA in a gel shift assay, suggesting an
unexpected mechanism of action. Lippard’s laboratory has also
developed a similar complex with platinum(IV) metal centers and
demonstrated enhanced cytotoxicity against the MCF-7 line.126
This approach represents an additional level of sophistication, as
the platinum(IV) metal center is reduced to platinum(II) within the
cell, leading to dissociation of the axial ligands, shedding of the
covalent linkage, and intracellular release of unmodified cisplatin.
This eliminates any possibility of interference with the mechanism
of the drug’s action.
In addition to biomolecules, several groups have used synthetic
polymers as drug vectors, either to improve pharmacological
properties at the systemic level, or to improve uptake at the
cellular level. Kataoka’s laboratory at the University of Tokyo
has led the development of cisplatin-incorporated polymeric
micelles, with microarray expression profiling suggesting that the
conjugates would have additional therapeutic benefits over free
cisplatin.127,128 Lippard’s laboratory has tethered their platinum(IV)
prodrug analogues of cisplatin to single-walled carbon nanotubes
(SWNT).129 Confocal microscopy experiments with fluorescently
labeled conjugates showed punctate staining, consistent with
cellular entry through endocytosis. Furthermore, AAS confirmed
the release of free cisplatin throughout the cell. Intracellular
concentration of the conjugates was increased six-fold with respect
to the unconjugated platinum complexes, and the conjugates
displayed enhanced toxicity versus cisplatin in the NTera-2 cell
line, even after normalization of platinum concentrations for the
polynuclear conjugates. Lin’s laboratory has developed nanoscale
coordination polymers of platinum(IV) prodrugs encased in silica
to provide a controlled release of cisplatin; cytotoxicity in
HT-29 cells was similar to that of cisplatin alone.130 Jaehde and
coworkers attempted to combat cisplatin resistance in A2780
ovarian carcinoma cells, which exhibit reduced cellular uptake,
by conjugating cisplatin to albumin and to PEG.131
Like any design effort, the rational development of biocon-
jugates is met by risk and opportunity. Active uptake has the
promise to increase intracellular concentrations dramatically and
to provide a basis of cellular specificity, but to remain effective, the
conjugate must escape endosomal trapping. Nuclear localization
signals may be able to direct conjugates more efficiently to
their targets, but the consequences of conjugation may alter
the functionality of the active moiety. Even seemingly innocent
structural changes, such as the length of the linker region or the
inclusion of a fluorophore can have dramatic effects on uptake
and localization that must be considered in order to deliver active
complexes successfully to their targets.
Conclusions
A variety of methods are useful in studying the cellular accumula-
tion ofmetal complexes. Flow cytometry and confocalmicroscopy
are complementary methods appropriate for luminescent com-
plexes, whereas ICP-MS or AAS must be used to study the overall
uptake of non-luminescent complexes. Metal complexes can enter
cells by passive diffusion, with the help of transport proteins,
or by endocytosis. Experiments with metabolic inhibitors can
differentiate between active and passive uptake mechanisms, while
channel inhibitors can differentiate between passive and facilitated
diffusion. Identification of the uptake mechanism can greatly aid
in the development of newdiagnostic and therapeutic applications.
Importantly, studies of cellular accumulation should not neglect
the issue of cellular efflux, which can render a diagnostic agent
useless or lead to clinical resistance in the therapeutic case.
Although a balance of uptake and efflux that leads to cellular ac-
cumulation is necessary for therapeutic activity, it is not sufficient.
Metal complexes must also be able to reach their target within
the cell, and presumably for DNA-targeted complexes, within the
nucleus. Several conjugation strategies have been developed to
improve the cellular accumulation and nuclear targeting of metal-
based agents; peptides, B vitamins, carbohydrates, and hormones
have all been covalently attached to metal moieties, most notably
cisplatin and its derivatives. These strategies also introduce new
challenges. For example, the covalent linkage must not interfere
with the mechanism of activity. The most sophisticated designs
are metabolized within the cell to release an active subunit. While
this approach offers promise, new strategies will be needed to
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control specific organelle targeting. Nevertheless, transition metal
complexes offer rich opportunities in the design of completely new
diagnostics and therapeutics, and thus various routes to cell entry
and organelle delivery need to be explored and exploited for a new
generation of versatile design.
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